• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»autoimmune hematology

Johnson & Johnson’s IMAAVY data sharpen the FcRn strategy beyond myasthenia gravis

By Pallavi Madhiraju on June 11, 2026   Pharma & Biotech  

Johnson & Johnson’s IMAAVY data sharpen the FcRn strategy beyond myasthenia gravis

Find out how Johnson & Johnson’s IMAAVY data could reshape treatment strategy in warm autoimmune hemolytic anemia.

Recent Posts

  • Could Phinomics’ circular DNA platform expose the blind spots slowing cancer drug development?
  • Volta Labs and Twist Bioscience push target enrichment closer to walk-away automation
  • Why Medtronic’s Scientia Vascular acquisition matters for stroke device workflows
  • Could Simcere’s Stanford Medicine IPF deal expose the next big gap in fibrosis treatment?
  • Acousia Therapeutics’ ACOU085 signal puts Kv7.4 activation in focus for hearing loss prevention
  • AbbVie’s Venclexta update puts long-term CLL treatment-free survival back in focus
  • Is Lateral Pharma’s pain platform quietly opening a new biotech battleground?
  • Why Akeso’s gumokimab approval could sharpen China’s psoriasis biologics race
  • Baxter faces FDA early alert as Volara circuit leakage risk threatens respiratory care
  • Penumbra’s THUNDERBOLT clearance strengthens Boston Scientific’s pending vascular device bet
  • Why Blood Cancer United’s luveltamab move could change rare pediatric cancer access
  • Amgen turns to Duke as FDA scrutiny puts Tavneos rare autoimmune disease role at risk
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes